Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
December 24, 2015
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
K Yong, J Cavet, P Johnson, et al.
Bone Marrow Transplantation
|
April 3, 2001
Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion
L Silberstein, A Davies, S Kelsey, et al.
British Medical Journal
|
March 15, 1975
Letter: A new service
R L Coppock, A J Cavenagh, K J Price, et al.
Psycho-Oncology
|
August 22, 2006
Mental health and other clinical correlates of euthanasia attitudes in an Australian outpatient cancer population
G L Carter, K A Clover, L Parkinson, et al.
International Journal of Laboratory Hematology
|
November 20, 2008
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma
F Davies, C Morris, J Bird, et al.
Blood Cancer Journal
|
July 26, 2012
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
T Ishii, T Seike, T Nakashima, et al.
Leukemia
|
September 20, 2011
Frequency of leukemic initiating cells does not depend on the xenotransplantation model used
J Vargaftig, D C Taussig, E Griessinger, et al.
British Journal of Haematology
|
June 19, 2001
Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients
E Matutes, G P Taylor, J Cavenagh, et al.
Leukemia Research Reports
|
December 28, 2013
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities
M Dennis, D Culligan, D Karamitros, et al.
British Journal of Cancer
|
September 6, 2017
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
J Cavenagh, H Oakervee, P Baetiong-Caguioa, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
December 24, 2015
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
K Yong, J Cavet, P Johnson, et al.
Bone Marrow Transplantation
|
April 3, 2001
Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion
L Silberstein, A Davies, S Kelsey, et al.
British Medical Journal
|
March 15, 1975
Letter: A new service
R L Coppock, A J Cavenagh, K J Price, et al.
Psycho-Oncology
|
August 22, 2006
Mental health and other clinical correlates of euthanasia attitudes in an Australian outpatient cancer population
G L Carter, K A Clover, L Parkinson, et al.
International Journal of Laboratory Hematology
|
November 20, 2008
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma
F Davies, C Morris, J Bird, et al.
Blood Cancer Journal
|
July 26, 2012
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
T Ishii, T Seike, T Nakashima, et al.
Leukemia
|
September 20, 2011
Frequency of leukemic initiating cells does not depend on the xenotransplantation model used
J Vargaftig, D C Taussig, E Griessinger, et al.
British Journal of Haematology
|
June 19, 2001
Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients
E Matutes, G P Taylor, J Cavenagh, et al.
Leukemia Research Reports
|
December 28, 2013
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities
M Dennis, D Culligan, D Karamitros, et al.
British Journal of Cancer
|
September 6, 2017
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
J Cavenagh, H Oakervee, P Baetiong-Caguioa, et al.
Page
of 5